The number needs its footnote
Human phase 3a · REDEFINE 1; published June 22, 2025
Which people—and which analysis—produced the weight-loss number?
Subject One unfurls a banner with a very large percentage and a very small footnote. Doctide swaps their sizes. “Now we can read it.” The visitor adds a blank line for the comparison group before hanging the banner.
What changes here
Weight-loss estimates depend on population and analysis. [1]
Read the study details & dates
NCT05567796 · Primary results published
The double-blind phase 3a trial randomized 3,417 adults without diabetes: BMI ≥30, or ≥27 with an obesity-related complication. Once-weekly subcutaneous cagrilintide–semaglutide (target 2.4 mg each) was compared with each component and placebo, with lifestyle intervention. Treatment-policy estimates, accounting for treatment discontinuation, were −20.4% body weight with the combination versus −3.0% with placebo; difference −17.3 percentage points (95% CI −18.1 to −16.6). [1]
What this does not establish
Group estimates are not individual predictions or valid rankings against differently designed trials.
Original sources
Sources reviewed November 3, 2026. Sponsor material is labeled; event dates are distinct from this editorial date. Trial identifiers identify the studies, not an invitation to enroll.
Subject One is fictional. Separate studies, species and populations are not a single patient’s experience. How to read the story